Menicon Co.,Ltd. FY2027 Q1 Earnings Report

Quick View

Executive Summary

Menicon’s Q1 of the fiscal year ending March 2027 posted higher revenue and earnings, with a substantial improvement in profitability. Revenue was ¥32.38B (+7.0% YoY), Operating Income was ¥3.43B (+74.9%), Ordinary Income was ¥3.36B (+90.1%), and Net Income was ¥2.23B (+124.9%). In addition to revenue growth in the core VisionCare Business, positive operating leverage drove earnings growth significantly above the rate of revenue growth, supported by the maintenance of the gross margin and a decline in the SG&A ratio.

Factors Affecting Business Performance

【Revenue】Revenue was ¥32.38B, representing a +7.0% YoY increase. The core VisionCare Business led overall performance with ¥30.21B in revenue (93.3% of total revenue, +7.1% YoY), while Other Businesses (Healthcare and Lifecare) also provided support with ¥2.16B in revenue (+6.4%).

【Profit and Loss】Operating Income was ¥3.43B (+74.9% YoY), and the Operating Margin improved to 10.6% from 6.5% in the previous year, a +4.1pt improvement. While maintaining a gross margin of 54.3%, the SG&A ratio declined to 43.7% from 46.8% in the previous year, and progress in fixed-cost absorption was the primary driver of earnings growth. Ordinary Income was ¥3.36B (+90.1%), and Net Income was ¥2.23B (+124.9%), with the magnitude of improvement expanding at each profit level. The difference between Ordinary Income and Net Income was primarily attributable to the effective tax rate of 33.6%; the impact of extraordinary gains and losses was minor (extraordinary gain of ¥0.002B and extraordinary loss of ¥0.004B). Revenue and earnings increased.

Segment Analysis

The VisionCare Business was the core contributor to consolidated earnings, generating revenue of ¥30.21B (+7.1% YoY), Operating Income of ¥5.19B (+42.7%), and a profit margin of 17.2%. Meanwhile, Other Businesses (Healthcare and Lifecare) generated revenue of ¥2.16B (+6.4%) but recorded an Operating Loss of ¥0.15B, representing an expansion of the loss YoY, with a profit margin of -6.7% as the businesses remain in an investment phase. After deducting company-wide expenses of ¥1.61B from the combined segment profits, consolidated Operating Income amounted to ¥3.43B. The business portfolio is highly concentrated in the VisionCare Business, meaning that market conditions and the competitive environment for this business have a significant impact on consolidated performance.

Key Financial Indicators

【Profitability】The Operating Margin improved to 10.6% from 6.5% in the previous year, a +4.1pt improvement, while the Net Profit Margin improved to 6.9% from 3.3%, a +3.6pt improvement. The gross margin was maintained at 54.3%, while the SG&A ratio declined to 43.7% from 46.8% in the previous year, and cost efficiencies contributed to the improvement in profitability.【Cash Quality】Cash and deposits amounted to ¥34.07B, increasing YoY. Operating Income-based interest coverage was approximately 15.8x against interest expenses of ¥0.22B, indicating sound debt-servicing capacity.【Investment Efficiency】ROE was 2.3% (on a single-quarter basis), and the total asset turnover ratio remained low. Construction in progress of ¥19.49B, representing approximately 20% of property, plant and equipment, indicates that the capital expenditure pipeline is temporarily constraining asset efficiency.【Financial Soundness】The Equity Ratio declined slightly to 47.3% from 48.5% in the previous year, while ample liquidity was secured with a current ratio exceeding 231%. Short-term borrowings were ¥6.56B, a substantial increase from ¥1.87B in the previous year, making trends in short-term financing an area requiring attention.

Cash Flow Analysis

As detailed disclosure of the cash flow statement is unavailable, funding trends are analyzed based on changes in the balance sheet. Cash and deposits increased to ¥34.07B from ¥32.61B in the previous year, indicating a trend toward accumulating cash on hand against the backdrop of improved Operating Income. Meanwhile, accounts receivable increased to ¥16.74B from ¥14.79B, and inventories (finished products) increased to ¥20.98B from ¥19.74B, indicating that working capital is expanding alongside revenue growth. Short-term borrowings increased substantially to ¥6.56B from ¥1.87B in the previous year, suggesting that working capital requirements and capital expenditure execution are being flexibly supported through short-term financing. Construction in progress increased to ¥19.49B from ¥16.68B in the previous year, indicating that capital expenditures continue to be implemented. Overall, while profitability at the operating level is improving, increases in inventories and accounts receivable are affecting funding efficiency, and future cash generation capacity is expected to depend on the management of working capital.

Quality of Earnings

Profit for Q1 was primarily generated by recurring business activities. Non-operating income was ¥0.17B (0.5% of revenue), including foreign exchange gains of ¥0.06B and dividend income of ¥0.02B, both limited in scale. Non-operating expenses were also ¥0.24B, including interest expenses of ¥0.22B, and had no significant impact. Extraordinary gains and losses were minimal, consisting of an extraordinary gain of ¥0.002B and an extraordinary loss of ¥0.004B, indicating that the earnings increase was attributable to improved efficiency in the core business. Although Net Income of ¥2.23B differed from Ordinary Income of ¥3.36B, this was primarily due to the burden of income taxes of ¥1.13B (effective tax rate of 33.6%), rather than non-recurring factors. Comprehensive Income was ¥3.18B, exceeding Net Income of ¥2.23B; the difference was attributable to foreign currency translation adjustments of ¥0.82B and valuation differences on securities of ¥0.13B, indicating that asset valuation in overseas operations had a positive impact on Comprehensive Income.

Earnings Forecast and Guidance

Progress against the full-year plan was 24.3% for revenue (plan: ¥133.00B), 31.2% for Operating Income (plan: ¥11.00B), and 32.0% for Ordinary Income (plan: ¥10.50B), with profit progress ahead of the simple progress benchmark of 25%. However, the full-year Ordinary Income plan assumes a -4.7% YoY decline, which differs in direction from the substantial increase of +90.1% in Q1, a point requiring attention. The company has made no revisions to either its earnings forecast or dividend forecast.

Shareholder Returns

The company’s announced full-year dividend forecast is ¥28.00 per share. Based on planned full-year EPS of ¥87.52, the Payout Ratio is approximately 32.0%. The financial foundation remains stable, with cash and deposits of ¥34.07B and an Equity Ratio of 47.3%; no revision to the dividend forecast was made during the quarter.

Risk Factors

1. Business concentration risk: The VisionCare Business accounts for 93.3% of revenue, creating a structure in which market fluctuations, the competitive environment, and regulatory trends concerning contact lenses in a single business directly affect consolidated performance.

2. Increase in working capital: Accounts receivable increased to ¥16.74B from ¥14.79B in the previous year, while inventories (finished products) increased to ¥20.98B from ¥19.74B, potentially indicating that funds are being tied up at a pace exceeding revenue growth. Trends in collections and inventory management will affect future cash generation capacity.

3. Increase in short-term financing: Short-term borrowings increased substantially to ¥6.56B from ¥1.87B in the previous year. Although this is believed to reflect financing for working capital and capital expenditure execution, interest-rate conditions and developments in the rollover policy could affect future financial costs.

Industry Benchmark (For Reference; Company Analysis)

Industry Benchmark (manufacturing)

Profitability and Return

The Operating Margin exceeds the industry median, while the Net Profit Margin is approximately in line with the median.

Growth and Capital Efficiency

The Revenue Growth Rate is slightly above the industry median.

※Source: Company analysis

Key Points from the Earnings Results

1. The Operating Margin improved to 10.6% from 6.5% in the previous year, a +4.1pt improvement, confirming positive operating leverage resulting from the decline in the SG&A ratio. Together with the maintenance of a 54.3% gross margin, improved efficiency in the cost structure was the primary driver of earnings growth.

2. Progress against the full-year plan exceeded the simple progress benchmark of 25% on the profit side, but the full-year Ordinary Income plan itself assumes a -4.7% YoY decline. Whether the Q1 growth rate will continue throughout the year must be confirmed through performance in subsequent quarters.

3. Accounts receivable and inventories increased simultaneously with a substantial increase in short-term borrowings. Trends in working capital during the earnings growth phase will be a key focus in assessing the linkage between earnings and cash flow.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly disclosed data using a residual income model (Ohlson-type model with an explicit 5-year fade). It does not represent a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥1,173–¥1,241 at ±1% for the cost of equity, and ¥1,203–¥1,208 at ±0.1 for ω.

Notes:

• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the quarter-end are used (there is a timing gap relative to the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model / Interest Rate Base Month: 2026-07 / This value does not forecast or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, and after consulting with a professional as necessary.

---End of Report---